S100A9 and Alzheimer disease: Both S100A9 and ApoE interact and co-aggregate with Aβ peptide, driving the amyloid-neuroinflammatory cascade in AD; therefore, those interactions may contribute to the cascade as a whole and modulate the development of AD pathology.